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Introduction
Sepsis remains a leading cause of death globally, with estimates of over 50.9 million cases resulting in over 5.3 million deaths each year (1) . Although accurate estimates are lacking, the burden of sepsis may be greatest in low-and middle-income countries (2) . In Africa, a systematic review and meta-analysis estimated that approximately 13.5% of hospitalized adult patients had a bloodstream infection (3).
Sepsis is defined as "life-threatening organ dysfunction due to a dysregulated host response to infection" (4) . Underlying this definition is the assumption that the host response to the infectious insult is uniform across pathogens and affected organ systems. However, sepsis is a complex syndrome caused by a wide range of microbial pathogens that results in disturbances of several organ systems. In the US, common causative bacterial pathogens include Escherichia coli, Staphylococcus aureus, and Streptococcus pneumoniae (5) . In Africa, additional common sepsis etiologies include non-typhoidal Salmonella and Mycobacterium tuberculosis, particularly in HIV-infected persons (3, 6) . Sepsis can originate from a range of infected sites, with the respiratory, genitourinary, and gastrointestinal tracts most frequently implicated (7) . Moreover, the signs and symptoms of sepsis are highly variable and typically non-specific, including aberrations in vital signs like tachycardia and tachypnea alongside signs of organ dysfunction, such as altered mental status, hypotension, and renal dysfunction, ultimately leading to shock and death. Ultimately, the pathogen, pathogen load, site of infection, and host susceptibility contribute to the clinical presentation and course of disease.
Failure to develop effective therapeutics and the limited success in developing diagnostic or prognostic tests are often attributed to the heterogeneity inherent in sepsis (8, 9) . There are currently no US Food and Drug Administration (FDA) approved treatments for sepsis, despite several decades of clinical trials. Activated protein C was FDA-approved but subsequently removed from the market after further studies failed to demonstrate a treatment effect.
Restricting the evaluation of candidate therapeutics to homogeneous subsets of patients, such as patients with a specific infectious etiology, has been proposed (8, 10) . However, despite widespread recognition that the pathogenic processes leading to organ failure and death often differ between microorganisms and infection source, most clinical trials continue to group together all patients with sepsis (9).
The current sepsis treatment strategies are based on evidence-based guidelines covering multiple domains of sepsis management including hemodynamics, infection, adjunctive therapies, metabolic factors, and ventilation (11) . Early recognition and treatment is considered paramount, as several studies have demonstrated an increased risk of mortality in patients receiving delayed treatment (12, 13) . However, early recognition of sepsis is difficult as physiologic derangements such as hypotension may be absent early in the course of illness. Biomarkers to aid in clinical recognition and prognostication are needed and extensive research in this area is ongoing.
A recent systematic review of sepsis identified 178 biomarkers that were altered during sepsis in 3,370 clinical and experimental studies (14) . The biomarkers encompassed a wide range of biologic pathways, including coagulation, the complement cascade, endothelial activation, inflammation, and apoptosis. The authors concluded that none of the biomarkers with published validity estimates had adequate sensitivity or specificity for use in clinical practice but combinations of biomarkers should be evaluated in future studies.
The role of the endothelium has increasingly been recognized as an integral component of the host response to sepsis. Involvement of the endothelium in sepsis is characterized by microvascular leak, which manifests clinically as hypotension, tissue edema, hypoperfusion, and organ dysfunction (15, 16) . During the course of infection, the endothelium becomes prone to clots, leukocyte trafficking increases, and the vessels become leaky (16) . The vascular leak resulting from endothelial activation is thought to contribute to the tissue hypoxia and organ dysfunction that are integral to the pathogenesis of sepsis. Compared to ICU controls, the capillaries of patients with sepsis have decreased or intermittent flow as well as decreased vascular density (15) . Several mechanisms have been proposed to account for the microcirculatory alterations, including dysfunction of the endothelium (15) .
Patient profiles based on patterns of circulating biomarkers of endothelial response may provide a clinically meaningful way to categorize patients into homogenous subgroups. In this study, we evaluated the role of 11 biomarkers for their clinical relevance and role in mechanistic pathways in a cohort of Ugandan adult patients with sepsis. Specifically, we evaluated with latent profile analysis (LPA) whether patients with sepsis can be characterized in patient subgroups, each with distinct endothelial response profiles. We also investigated the clinical relevance of the observed endothelial response profiles. Lastly, we investigated with latent factor analysis (LFA) whether the host response to any infectious insult is uniform across all patients by exploring whether specific endothelial markers were part of one coordinated process or several distinct processes.
Results

Patient Characteristics
A total of 426 patients were enrolled in the PRISM-U2 study, of whom 315 had complete biomarker values and outcome measures available for analysis (Figure 1) . The demographic and clinical characteristics of the full sample and the analysis sample were comparable (Table 1 ). All remaining analyses were conducted using the analysis set (N=315). The median patient age was as well as between sICAM1 and CXCL10.
Patient subgroups and mortality
Several fit-statistics were evaluated to determine the number of classes (i.e. patient subgroups) ( Table 2 ). The four-class model had slightly lower log likelihoods, AIC, and BIC statistics than the three-class model. However, the Lo-Mendell-Rubin test indicated there was no improvement in fit for a four-class versus a three-class model. Furthermore, the entropy of the three-class model was higher, suggesting higher classification certainty. Based on these results, a three-class model was selected.
Profile 1 was the most prevalent, comprising 39% of the patients (N=122). Thirty-four percent of the patients had a biomarker profile consistent with Profile 3 (N=107) and 27% with Profile 2 (N=86). The three groups were similar in their demographic characteristics ( Similarly, the RR of Profile 2 versus 1 increased 3 times with every 1 unit increase in logtransformed PCT (95%CI: 2.07, 4.50), controlling for age, sex and CD4 + T cell count.
Endothelial processes
The principal components analysis (PCA) parsed the data into 11 components, 4 of which had eigenvalues greater than 1 suggesting that a maximum of 4 latent factors should be retained. The The uniqueness of most biomarkers (i.e., the proportion of the variance that was not explained by the factors) was moderate, indicating that the variance in the biomarkers was partially explained by the four factors (Table 6 ). In particular, the high factor loadings of all three biomarkers comprising Factor 2 suggests that this factor was a strong predictor of ANGPT1, PF4, and VEGF. Two of the biomarkers (sFLT1 and VWF) had uniqueness values greater than 0.6, suggesting that there was a greater level of residual variability in these biomarkers. Factor 4 was identified by only two biomarkers and is, therefore, at risk for misinterpretation.
Patients fitting Profile 1 had biomarker concentrations that were below average for all 11 biomarkers (Table 3 and Figure 3 ). The biomarkers identified through the latent factor analysis (LFA) as belonging to Factor 2 (ANGPT1, PF4, and VEGF) were particularly low in Profile 1. 
Discussion
Sepsis is widely recognized as a complex, heterogeneous syndrome (9) . A panel of biomarkers involved in the endothelial response to sepsis was rigorously evaluated to better characterize the underlying heterogeneity in the pathways of host response and injury that underlie multi-organ dysfunction and mortality in sepsis.
Three subgroups of patients with sepsis were identified with distinct host endothelial response profiles. The patients in the three subgroups were similar in their demographic characteristics, yet there were significant differences in their clinical laboratory values. This finding suggests that there is clinical relevance to the three endothelial response profiles. Profile 2 was associated with low CD4 + T cell counts, low platelet counts, low hemoglobin concentrations, and elevated WBC counts. In contrast, the risk of being in the Profile 3 group increased with increasing hemoglobin concentrations and platelet counts.
Patients infected with MTB were at approximately 2.5 times higher risk of being in Profile 2 compared to patients without MTB bacteremia, controlling for age, sex, and CD4 + T cell count.
This finding supports the theory that different pathogens may elicit different endothelial responses. However, only 38% of patients estimated to be in Profile 2 based on most likely class membership were infected with MTB, suggesting that the endothelial response is not pathogen specific. Few studies have specifically investigated endothelial activation in patients with MTB.
Ragno, et al., examined changes in gene expression in macrophages infected with MTB and found upregulation of genes encoding VEGF and its receptor sFLT1, among other genes thought to be involved in immunoregulation (17) . VEGF (18, 19) and sICAM1 (20) concentrations were also found to be higher in patients with active than inactive pulmonary tuberculosis. Patients with active pulmonary tuberculosis had significantly higher concentrations of PF4 than control patients (21, 22) , and one study found PF4 levels correlated with the extent of pulmonary lesions on chest radiography (22) . In a study of patients with pleural effusions, VWF levels were significantly higher in patients with tuberculosis than other etiologies (23) . Among patients with pulmonary MTB, sTREM1 concentration ≥128 pg/mL was associated with 6-month mortality and the presence of disseminated tuberculosis (24), but did not differentiate tuberculosis from pneumonia caused by extracellular bacteria (25) . Although the evidence for the contribution of endothelial dysfunction to MTB pathogenesis is limited, further investigation may be warranted, particularly as most studies focused on pulmonary (rather than extra-pulmonary) tuberculosis. Latent factor analysis of the correlation structure of the biomarkers identified patterns suggesting that the biomarkers are involved in four distinct processes. Factor 1 was loaded highly by the biomarkers CHI3L1, sTREM1, and sFLT1. All three are involved in the monocyte response to infection. sTREM1 and sFLT1 are receptors expressed on monocytes, which lead to secretion of proinflammatory mediators when activated. Factor 1 could, therefore, be interpreted as an inflammatory process. sTREM1 amplifies the inflammatory response in extracellular bacterial and fungal infections (27) . Once activated, the cellular receptors are shed from the cell surface.
Activated macrophages and neutrophils secrete CHI3L1, which has a proinflammatory effect.
While the biologic activity of CHI3L1 is not completely understood, it is associated with inflammatory conditions such as rheumatoid arthritis and has been shown to upregulate VEGF expression and promote angiogenesis (28).
ANGPT1, PF4, and VEGF loaded on Factor 2, which could be interpreted as a vessel stabilization process. All three molecules are involved in angiogenesis, the formation of blood vessels from pre-existing blood vessels. Prior investigation of the biologic relationship between ANGPT1 and VEGF found that ANGPT1 prevents VEGF from disrupting endothelial cell to cell contacts, thus stabilizing blood vessels and preventing vascular leak (29) . PF4 has several biological functions and inhibits the angiogenic effects of VEGF (30) . Furthermore, a murine model of sepsis-induced acute lung injury demonstrated that disruption of PF4 prevented lung edema and tissue damage (31) . Given the biologic functions of the constituent biomarkers, this factor likely plays a protective role in sepsis pathogenesis.
Factor 3 was characterized by high loadings of CXCL10, VWF, and sICAM1, and could be interpreted as a leukocyte recruitment process. Trans-endothelial migration of leukocytes to sites of inflammation occurs in a multi-step process involving rolling across the endothelium, integrin activation to stop leukocyte motility, and adhesion and transmigration of the cell across the endothelium. The processes of leukocyte rolling and leukocyte adhesion have both been shown to be dependent on the presence of VWF in inflamed veins (32) . CXCL10 is a chemokine that is produced at high levels by activated endothelial cells and is involved in leukocyte transmigration (33) . The firm adhesion of leukocytes to the endothelial cell is mediated by sICAM1, an adhesion molecule expressed on endothelial cells.
Lastly, high loadings of ANGPT2 and sTEK characterized Factor 4, which could be interpreted as endothelial vessel instability. ANGPT2 competes with ANG-1 for their receptor, sTEK. When bound to sTEK, ANGPT2 primes the endothelium to respond to proinflammatory and angiogenic (e.g., VEGF) stimuli, propagating further endothelial activation and destabilizing the endothelial vasculature (34) . Endothelial barrier integrity is tightly regulated and is altered during sepsis.
ANGPT2 and sTEK signaling plays a critical role in disrupting the endothelial barrier resulting in net extravasation of fluid from the vascular space into the tissues (35).
The four-factor model explained the variability in most of the biomarkers, however, sFLT1 and VWF had high uniqueness values. It is possible that these biomarkers are involved in other relevant processes not captured in this analysis. Alternatively, these biomarkers may be more difficult to accurately measure. Factor 4 (vessel instability) was identified by only two biomarkers and is therefore at risk for misinterpretation. However, there has been extensive study on the relationship between ANGPT2 and its receptor, sTEK, supporting the interpretation of this factor as vessel instability.
Interpretation of the endothelial response profiles is complex. Patients fitting Profile 1 had below average concentrations for all 11 biomarkers, suggesting a quiescent phenotype. In particular, biomarkers belonging to Factor 2 (ANGPT1, PF4, and VEGF), interpreted as the vessel stabilization factor, were particularly low in Profile 1. Profile 2 was characterized by elevated concentrations of all biomarkers except for those belonging to the vessel stabilization factor (Factor 2). Profile 2 could be interpreted as endothelial dysfunction. Conversely, Profile 3 consisted of elevated concentrations of biomarkers belonging to Factor 2 and low concentrations of the other biomarkers, perhaps suggesting that these patients fit an endothelial repair profile.
The cytokine responses for patients with sepsis were summarized in a review to typically follow one of three patterns: 1) rapid production of both pro-inflammatory and anti-inflammatory cytokines; 2) predominance of anti-inflammatory cytokines; or 3) globally depressed production of cytokines (36) . Future studies could investigate whether the three cytokine patterns described in the review correspond to the endothelial response profiles identified in this study.
LFA and LPA offer a novel approach to understanding the host-response profiles in patients with sepsis. LFA provides information on the correlation structure of the biomarkers, where correlated biomarkers can be conceptualized as being part of a biologic process. LPA identifies subgroups of patients with similar host-response profiles. The use of both approaches in parallel provides insight into the biologic processes underlying the patient subgroups. In contrast, other methods often used in biomarker studies, such as logistic regression, provide information on the relationship between individual analytes and the outcome. In complex diseases such as sepsis, however, the outcome is likely a result of disruption in multiple biologic processes, which may not be well represented by individual analytes. Furthermore, traditional methods do not account for subgroups of patients that differ in their biomarker profiles and their risk of the outcome.
However, LFA and LPA do have limitations. The decisions regarding both the number of factors as well as the number of subgroups were guided by several well-established criteria but are ultimately somewhat arbitrary. In the LFA, we chose a four-factor model, but an argument could also be made for a three-factor solution. While selecting too few or too many factors, both have consequences for the interpretation of the data. Specifying too many factors could lead to inclusion of minor factors but was considered more acceptable than potentially losing important information by specifying too few factors. Furthermore, the fourth factor was comprised of ANG-2 and its receptor sTEK, which is conceptually consistent with the known biology of the two molecules. In the LPA, the log-likelihood and BIC were marginally better for the four-class solution. However, simulation studies suggest that the Lo-Mendell-Rubin test is more accurate for selecting the correct number of classes. In addition, the entropy statistic suggested that the three-class solution formed more distinct groups.
While our study had a number of strengths, it also had limitations, including that it was a single country study that enrolled patients who were predominantly people living with HIV. We hypothesize that the biological processes we observed in patients with sepsis in Uganda will be conserved across other patient populations; however, additional prospective confirmatory studies are required in geographically diverse areas to establish the generalizability of our findings. In this study, we focused on endothelial and immune activation during sepsis. 
Methods
Study population
The primary cohort from which these biomarker data were collected has been described elsewhere (37) . In brief, 426 adult patients admitted with sepsis to the medical wards of two Ugandan hospitals were enrolled in an intervention study of fluid resuscitation conducted between May, 2008 and May, 2009.
Data Collection
The primary outcome of interest was 28-day mortality, measured in days from study enrollment.
Demographic, clinical history, and patient management data were systematically recorded in the evaluation. Double data entry was conducted for quality control using EpiData TM (The EpiData Association, Odense, Denmark).
Laboratory Testing
Blood samples were collected at the time of enrollment for complete blood counts, electrolytes, CD4+ T-cell (CD4) counts, HIV serology, malaria blood smears, and blood cultures (both aerobic and mycobacterial).
All biomarker assays were conducted at the University of Toronto using blood drawn at study enrollment. The clinical samples were centrifuged at the hospital, and serum was stored at -20°C.
Commercial enzyme-linked immunosorbent assays were used to measure biomarker levels (ANGPT1, ANGPT2, sICAM1, sTREM1, CHI3L1, PF4, CXCL10, sFLT1, sTEK, VEGF: R&D Systems, Minneapolis, MN; VWF: antibody from Dako, Carpinteria, CA, standard from American Diagnostica, Stamford, CT) (38) . All assays were conducted in duplicate. The biomarker results were reported on a continuous scale, measured in either picograms or nanograms per milliliter. The upper and lower limits of detection for each assay were: ANGPT1
(0.039 -20 ng/mL); ANGPT2 (0.016-8 ng/mL); sICAM (0.078-4 ng/mL); sTREM1 (93.8-6,000 pg/mL); CHI3L1 (31.2-2,000 pg/mL); PF4 (15.6-1,000 pg/mL); CXCL10 (31.2-2,000 pg/mL); sFLT1 (125-8,000 pg/mL); sTEK (156-10,000 pg/mL); VEGF (31.2-2,000 pg/mL); VWF (1.95-2000 ng/ mL).
Statistics
The analysis set included the 426 patients enrolled in the prospective study (the "full sample"), excluding patients missing mortality data (5) A series of latent profile models was evaluated to determine the number of latent subgroups.
Several criteria were used to determine the best fitting model, including the Bayesian Information Criterion (BIC) (39, 40) , the log likelihood, the Lo-Mendell-Rubin test, (41) entropy (42), and clinical interpretability (43) . Once the optimal number of classes was determined, subjects were assigned to the most-likely class based on the posterior probability of class membership. Multinomial logistic regression using a three-step approach was used to investigate the demographic and clinical characteristics of the latent subgroups. These models provide the risk of membership in a given latent class versus a reference latent class, with the corresponding confidence interval. The three-step approach was used to account for the measurement error in the classification of patients into their most-likely class (44) . Age, sex, and the natural logarithm of the CD4 + T cell count were included in the models as potential confounders. M-plus v.7
(Muthén and Muthén, Los Angeles, CA) was used to identify the best fitting LPA model and for multinomial logistic regression analysis. Kaplan-Meier survival curves were generated for each latent class, and the log-rank test was used to test whether the survival curves were significantly different. All statistical tests were two tailed, with a p value < 0.05 considered significant.
To evaluate whether the endothelial response to sepsis consisted of one unified biological process or multiple processes, latent factor analysis (LFA) was used to analyze the correlation structure of the biomarkers. LFA is a multivariate statistical method for determining the number and nature of patterns of an observed correlation structure. In this study, each factor represented an underlying biological process comprising a set of correlated biomarkers. Principal components analysis (PCA) was used to estimate the number of dimensions of shared variation.
The number of components were determined using several criteria, including: the proportion of variance explained by the component (45) , having an eigenvalue greater than one (46) , scree plots analysis (47) , and parallel analysis (PA) (48) . The criterion of an eigenvalue greater than one was used as an upper bound for the number of factors to retain (45) . In PA, 1000 datasets were simulated with the same number of observations and variables as the study dataset. As the generated data were random, any correlation in the indicators was due to sampling error.
Components corresponding to eigenvalues greater than the random eigenvalues obtained from the PA were retained. Components corresponding to eigenvalues less than or equal to the random eigenvalues were considered to be due to sampling error (45) . The iterated principal factor method was then used to estimate factor model loadings for the selected number of factor dimensions. Since correlation among biomarkers within the biologic processes was expected, a promax rotation was used (49) . Factor rotations simplify the factor structure and interpretability.
The rotated factor pattern matrix was used to interpret the meaning of the factors. The rotated factor loadings in this matrix were standardized regression coefficients, representing the correlation between a biomarker and the factor, holding other factors constant. Table 6 . Rotated Factor Pattern (Promax Rotation). Bold indicates high factor loadings.
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